Tolvaptan
Indication
Autosomal dominant polycystic kidney disease (NICE TA358)
NICE TA358 - Tolvaptan for treating autosomal dominant polycystic kidney disease
Red
Brand:
Jinarc
Nice TA:
358
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Endocrine system
Background
Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if:
- they have chronic kidney disease stage 2 or 3 at the start of treatment
- there is evidence of rapidly progressing disease and
- the company provides it with the discount agreed in the patient access scheme.
NHS England is the commissioner of dialysis and kidney transplants, hyponatraemia and other endocrine uses.